Please assess the completion status of the following clinical trial:

Trial Title: A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's parent has provided informed consent and subject has provided assent~* Children Age 2 to less than 18 years~* Diagnosed with chronic kidney disease~* Diagnosed with secondary hyperparathyroidism receiving hemodialysis,~* Weighing at least 7 kg~* Laboratory results within specified range.~Exclusion Criteria:~* Currently receiving treatment in another investigation device or drug study~* Subject has received cinacalcet therapy within 30 days~* History of prolongation QT interval~* Subject is taking any medications that are on the QT prolongation medication list~* Electrocardiograph (ECG) measurements within specified range.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Etelcalcetide (Type: EXPERIMENTAL): Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).